Curis Provides Fourth Quarter 2022 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Related Keywords

United States ,Roche Erivedge ,James Dentzer ,Genentech ,Drug Administration ,Nasdaq ,Curis Inc ,Exchange Commission ,Prnewswire Curis Inc ,Roche Group ,Company Takeaim Leukemia ,Takeaim Leukemia ,Recommended Phase ,Chief Executive Officer ,Recent Operational ,Complete Remission ,Partial Hematologic ,Objective Response ,Aim Lymphoma ,Aim Leukemia ,Orphan Drug Designation ,Note Regarding Forward Looking Statements ,Securities Litigation Reform Act ,Takeaim Lymphoma ,Oberland Capital ,Curis ,Nc ,Pharmaceuticals ,Health Care Amp Hospitals ,Biotechnology ,Medical Pharmaceuticals ,Earnings ,